Why did reported EPS fall 17.6% while adjusted EPS rose 13.6%?

The gap reflects non-GAAP adjustments of roughly $1.15 per share in Q1 2025. The largest items were a $139 million stock compensation payment triggered by the Inari change of control, amortization of purchased intangibles ($0.35 per share), and goodwill and other impairments, plus inventory step-up, structural optimization, and recall-related charges. Management notes these items are irregular in timing and may not reflect ongoing performance.

Did Stryker change its full-year 2025 guidance?

Yes, in mixed directions. Organic sales growth guidance was raised to 8.5%-9.5%. Adjusted EPS guidance was lowered to $13.20-$13.45 from $13.45-$13.70, because the company is absorbing roughly $200 million of tariff impact, while the prior guidance already included $0.20-$0.30 of Inari dilution.

How did the Inari Medical acquisition affect Stryker's financials?

The acquisition was funded largely with debt. Acquisitions used $4.7 billion of cash in the quarter, long-term debt increased about $2.2 billion, and goodwill and intangibles rose about $5 billion. Management expects dilution to 2025 adjusted EPS, and integration and change-of-control costs have already affected reported results.

Is Stryker's core business still growing strongly?

Yes. Organic growth of 10.1% was broad-based, with U.S. reported sales up 13.4% and international up 7.3% (10.8% in constant currency). Vascular grew 31% in the U.S. and 67% internationally on an as-reported basis, largely due to Inari, while Knees, Hips, and Trauma and Extremities also grew, and Spinal Implants declined 2.9%.

What are the main risks investors should monitor?

Key risks include the tariff impact on margins, integration of Inari and realization of its expected benefits, higher leverage after the debt-funded acquisition, inventory build ($1.1 billion increase in the quarter), and ongoing recall, regulatory, and legal matters. Cash from operations is modest relative to earnings, so working capital and deleveraging will be important to watch.

SYK 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed May 1, 2025. Cited figures are marked; the original filing is the authoritative source.

Stryker reported a solid first quarter 2025 with reported net sales up 11.9% to $5.9 billion^a (10.1% organic growth, 9.4% from unit volume), led by MedSurg and Neurotechnology (+13.4% reported, +10.7% organic) and Orthopaedics (+9.7% reported, +9.3% organic).

Adjusted operating margin expanded 100 bps to 22.9% and adjusted EPS rose 13.6% to $2.84^b, while reported EPS fell 17.6% to $1.69 due to acquisition and integration charges, amortization of intangibles, impairments, and a $139 million stock compensation payment triggered by the Inari Medical change of control. Reported operating income declined 13.9% to $837 million, with reported operating margin of 14.3% versus 18.5% a year earlier. Management raised full-year 2025 organic net sales growth guidance to 8.5%-9.5%, citing strong demand for capital products and procedural volumes.

Adjusted EPS guidance was lowered to $13.20^c-$13.45 from $13.45-$13.70, as management absorbed roughly $200 million of tariff impact, with the prior guidance already inclusive of Inari dilution of $0.20-$0.30 per share. The balance sheet changed materially: long-term debt rose to $14.4 billion from $12.2 billion, and goodwill and intangibles increased to $25.2 billion from $20.3 billion following the Inari acquisition, which required roughly $4.7 billion in cash. Cash and equivalents fell to $2.3 billion.

Operating cash flow was $250 million^d, up from $204 million, though it remains modest relative to earnings given working capital build, including a $1.1 billion increase in inventories. Investors will likely focus on whether the tariff headwind is contained, the pace of Inari integration, and deleveraging.

02—Key points

Key Highlights

Reported net sales rose 11.9% to $5.9 billion; organic growth of 10.1% was driven mainly by unit volume (9.4%), with MedSurg and Neurotechnology growing 10.7% organically and Orthopaedics 9.3%.
Adjusted operating margin expanded 100 bps to 22.9%, while reported operating margin fell to 14.3% from 18.5% due to acquisition-related charges, including a $139 million stock compensation payment tied to the Inari change of control.
Adjusted EPS grew 13.6% to $2.84; reported diluted EPS declined 17.6% to $1.69.
Full-year 2025 organic net sales growth guidance raised to 8.5%-9.5%, citing strong capital product demand and procedural volumes.
Adjusted EPS guidance lowered to $13.20-$13.45 from $13.45-$13.70 to absorb an estimated ~$200 million tariff impact, with prior guidance already including Inari dilution.
Acquisition of Inari Medical (~$4.7 billion cash outflow) lifted goodwill and intangibles to $25.2 billion and long-term debt to $14.4 billion, from $12.2 billion at year-end 2024.
Operating cash flow was $250 million versus $204 million a year ago, while inventories rose to $5.1 billion from $4.8 billion.

03—Questions

Frequently Asked Questions

Why did reported EPS fall 17.6% while adjusted EPS rose 13.6%?
The gap reflects non-GAAP adjustments of roughly $1.15 per share in Q1 2025. The largest items were a $139 million stock compensation payment triggered by the Inari change of control, amortization of purchased intangibles ($0.35 per share), and goodwill and other impairments, plus inventory step-up, structural optimization, and recall-related charges. Management notes these items are irregular in timing and may not reflect ongoing performance.
Did Stryker change its full-year 2025 guidance?
Yes, in mixed directions. Organic sales growth guidance was raised to 8.5%-9.5%. Adjusted EPS guidance was lowered to $13.20-$13.45 from $13.45-$13.70, because the company is absorbing roughly $200 million of tariff impact, while the prior guidance already included $0.20-$0.30 of Inari dilution.
How did the Inari Medical acquisition affect Stryker's financials?
The acquisition was funded largely with debt. Acquisitions used $4.7 billion of cash in the quarter, long-term debt increased about $2.2 billion, and goodwill and intangibles rose about $5 billion. Management expects dilution to 2025 adjusted EPS, and integration and change-of-control costs have already affected reported results.
Is Stryker's core business still growing strongly?
Yes. Organic growth of 10.1% was broad-based, with U.S. reported sales up 13.4% and international up 7.3% (10.8% in constant currency). Vascular grew 31% in the U.S. and 67% internationally on an as-reported basis, largely due to Inari, while Knees, Hips, and Trauma and Extremities also grew, and Spinal Implants declined 2.9%.
What are the main risks investors should monitor?
Key risks include the tariff impact on margins, integration of Inari and realization of its expected benefits, higher leverage after the debt-funded acquisition, inventory build ($1.1 billion increase in the quarter), and ongoing recall, regulatory, and legal matters. Cash from operations is modest relative to earnings, so working capital and deleveraging will be important to watch.

04—Continue

← View all 8-K filings